Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.

Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators..

Circulation. 2003 Jan 28;107(3):437-42.

2.

Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.

Lenderink T, Boersma E, Heeschen C, Vahanian A, de Boer MJ, Umans V, van den Brand MJ, Hamm CW, Simoons ML; CAPTURE Investigators..

Eur Heart J. 2003 Jan;24(1):77-85.

PMID:
12559939
3.

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML.

N Engl J Med. 1999 May 27;340(21):1623-9. Erratum in: N Engl J Med 1999 Aug 12;341(7):548.

4.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

5.

Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.

Ibbotson T, McGavin JK, Goa KL.

Am J Cardiovasc Drugs. 2003;3(5):381-6. Review.

PMID:
14728074
6.
9.

Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.

Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, Armstrong PW, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators..

Am Heart J. 2004 May;147(5):865-73.

PMID:
15131544
10.
12.
13.

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators..

JAMA. 2006 Apr 5;295(13):1531-8. Epub 2006 Mar 13.

PMID:
16533938
14.

Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS.

Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators..

Eur Heart J. 2004 Sep;25(17):1494-501.

PMID:
15342168
15.
16.

Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.

James S, Armstrong P, Califf R, Husted S, Kontny F, Niemminen M, Pfisterer M, Simoons ML, Wallentin L.

Eur Heart J. 2002 Oct;23(19):1538-45.

PMID:
12242074
17.

Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.

De Servi S, Mariani M, Vandoni P, Dellavalle A, Politi A, Poletti F, Bonizzoni E, Leoncinie M; Registro Osservazionale Angina Instabile (ROSAI-2) Investigators..

J Cardiovasc Med (Hagerstown). 2006 Mar;7(3):159-65.

PMID:
16645379
18.

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.

N Engl J Med. 1999 Jul 29;341(5):319-27.

19.
20.

Supplemental Content

Support Center